Top Tweets for #csPC

2 months ago

Darolutamide alone for nonmetastatic #CSPC: 52-week safety and efficacy results from the #ARAMON trial. @alaccetti @nyulangone joins @TDorffOnc @cityofhope to discuss the 52-week results from ARAMON, a phase 2 study of darolutamide monotherapy in biochemically recurrent and low-volume metastatic prostate cancer. #WatchNow > https://t.co/ZrUKkNV2s5

0

9

3

4

1K

Chhattisgarh State Power Companies @CSPwrCompanies

3 months ago

Darolutamide alone for nonmetastatic #CSPC: 52-week safety and efficacy results from the #ARAMON trial. @alaccetti @nyulangone joins @TDorffOnc @cityofhope to discuss the 52-week results from ARAMON, a phase 2 study of darolutamide monotherapy in biochemically recurrent and low-volume metastatic prostate cancer. #WatchNow > https://t.co/ZrUKkNV2s5

0

14

3

6

2K

6 months ago

🇮🇳 Republic Day 2026 🇮🇳 Flag hoisting at CSPC HQ, Dangania, Raipur by Dr. Rohit Yadav (IAS). Present: Rajesh Kumar Shukla, S. K. Katiyar & Bhimsingh Kanwar. Officers & employees participated in large numbers. #RepublicDay2026 #CSPC #JaiHind #GPatel

1

2

1

0

113

Ottawa Science Policy Network @OttawaSciPolNet

9 months ago

🌎Comment évolue la #CollaborationScientifique dans une ère de transition géopolitique? 🎤Notre VP de média sociaux, Alexa D’Addario, anime l’épisode la plus récente du podcast de @sciencepolicy https://t.co/A7uJqS8JxX #SciPol #OSPN #CSPC #ScienceDiplomacy #InternationalRelations

0

2

1

0

111

Ottawa Science Policy Network @OttawaSciPolNet

9 months ago

🌎How is international #ScienceCollaboration evolving in an age of geopolitical shifts? 🎤Our very own VP of Social Media, Alexa D’Addario, hosts the latest @sciencepolicy podcast: https://t.co/A7uJqS8JxX #SciPol #OSPN #CSPC #ScienceDiplomacy #InternationalRelations

OttawaSciPolNet's tweet photo. 🌎How is international #ScienceCollaboration evolving in an age of geopolitical shifts?
🎤Our very own VP of Social Media, Alexa D’Addario, hosts the latest @sciencepolicy podcast: https://t.co/A7uJqS8JxX
#SciPol #OSPN #CSPC #ScienceDiplomacy #InternationalRelations https://t.co/Iv93ApaOBZ

1

2

0

147

❥𝐀𝐫𝐩𝐢𝐭𝐚 @ArpitaCreations

9 months ago

Prithvi ✘ Sanyogita // Ajeeb o gareeb tarkeeb lagaye naseeb💗 #CSPC #PrithvirajChauhan #Sanraj

6

23

5

2K

三角そうた　前衆議院議員　埼玉16区 @misumikouenkai1

9 months ago

先ほどは米国の有力シンクタンクCSPCのグレンナイ代表(元下院議員)と懇談する機会を頂きました。日米関税交渉や米民主党のこれからの戦略、日本の政治状況について意見交換致しました。国内政局が激しく動く中ですが、海外にも目を配りつつ政治を進めて参ります。 #CSPC

misumikouenkai1's tweet photo. 先ほどは米国の有力シンクタンクCSPCのグレンナイ代表(元下院議員)と懇談する機会を頂きました。日米関税交渉や米民主党のこれからの戦略、日本の政治状況について意見交換致しました。
国内政局が激しく動く中ですが、海外にも目を配りつつ政治を進めて参ります。
#CSPC https://t.co/663mLtzhzk

0

23

4

0

11 months ago

The New Drug Application (#NDA) for semaglutide injection developed by 🇨🇳 #CSPC has been officially accepted by 🇨🇳 #NMPA. The semaglutide API used in CSPC’s product is entirely synthesized via chemical methods. Several other semaglutide biosimilar products have also been submitted for market approval in China, including those from Jiuyuan Gene, Livzon Pharmaceutical, Qilu Pharmaceutical, United Laboratories, and Huadong Medicine/PEG-BIO Biopharm.

0

9

1

957

Columbus Community Hospital @columbushosp

12 months ago

$MDGL Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist SYH2086 with #CSPC https://t.co/3C9YBszegt CSPC has granted Madrigal an exclusive global license to develop, manufacture, and commercialize SYH2086. upfront $120 million milestone $2 billion SYH2086, a preclinical candidate developed by the CSPC with complete global intellectual property rights, is a novel oral small molecule GLP-1 receptor agonist. #licensing #MASH #China

1

11

2

2K

12 months ago

Huge congratulations to our Athletes of the Month for July! We're incredibly proud of the dedication, hard work and inspiring achievements shown by all our athletes this month. Your commitment truly shines through. #CSPC #AthleteOfTheMonth #JulyAthletes #SportsExcellence

columbushosp's tweet photo. Huge congratulations to our Athletes of the Month for July! We're incredibly proud of the dedication, hard work and inspiring achievements shown by all our athletes this month. Your commitment truly shines through.

#CSPC #AthleteOfTheMonth #JulyAthletes #SportsExcellence https://t.co/1jWU9zLbQ8

0

9

0

287

St. Bernard - TCDSB @StBernardsTCDSB

about 1 year ago

AstraZeneca $AZN enters strategic collaboration with 🇨🇳 #CSPC Pharmaceuticals focused on AI-enabled research https://t.co/ti8LC19ctU AstraZeneca and CSPC agree to discover and develop pre-clinical candidates for multiple targets with the potential to treat diseases across chronic indications, including a pre-clinical small molecule oral therapy for immunological diseases. upfront $110 million development milestone $1.62 billion sales milestone $3.6 billionpayments, single digit royalties AstraZeneca will have rights to exercise options for exclusive licenses to develop and commercialise worldwide candidates identified under this agreement. The research will be carried out by CSPC, in Shijiazhuang City and will utilise their AI-driven, dual-engine efficient drug discovery platform.

0

5

0

1

585

about 1 year ago

#WeCelebrate the year with a #CSPC sponsored BBQ day! #Thanks to our caring CSPC who support and feed our students well. Well served by @_mrcorn

StBernardsTCDSB's tweet photo. #WeCelebrate the year with a #CSPC sponsored BBQ day! #Thanks to our caring CSPC who support and feed our students well. Well served by @_mrcorn https://t.co/WneMvPeLsU

1

5

1

0

999

about 1 year ago

Advances and challenges in high-risk #CSPC: a multidisciplinary approach to patient management. Paul Sieber joins Neal Shore to discuss risk stratification for patients with hormone-sensitive or castration-sensitive disease > https://t.co/yx14ySV0XT @BayerPharma

urotoday's tweet photo. Advances and challenges in high-risk #CSPC: a multidisciplinary approach to patient management. Paul Sieber joins Neal Shore to discuss risk stratification for patients with hormone-sensitive or castration-sensitive disease > https://t.co/yx14ySV0XT @BayerPharma https://t.co/MEVNO9I7u9

0

4

1

0

781

about 1 year ago

🇨🇳 #CSPC issued an announcement stating that it is currently in discussions with several independent third parties regarding three potential transactions. These involve the licensing and collaboration on the development, manufacturing, and commercialization of certain CSPC products, including an EGFR-ADC and other drug candidates developed through CSPC’s proprietary technology platforms. #deal https://t.co/PyCIhGgiU0 For each of the potential transactions, the aggregate amount of potential upfront payments, development milestone payments, and commercialization milestone payments to CSPC could total up to approximately $5 billion. One of the three transactions is currently in its late-stage negotiation phase and is expected to be finalized by June 2025. CSPC’s EGFR ADC candidate, CPO301, is currently in Phase III clinical trials.

chuminhua432's tweet photo. 🇨🇳 #CSPC issued an announcement stating that it is currently in discussions with several independent third parties regarding three potential transactions. These involve the licensing and collaboration on the development, manufacturing, and commercialization of certain CSPC products, including an EGFR-ADC and other drug candidates developed through CSPC’s proprietary technology platforms. #deal
https://t.co/PyCIhGgiU0

For each of the potential transactions, the aggregate amount of potential upfront payments, development milestone payments, and commercialization milestone payments to CSPC could total up to approximately $5 billion. One of the three transactions is currently in its late-stage negotiation phase and is expected to be finalized by June 2025.

CSPC’s EGFR ADC candidate, CPO301, is currently in Phase III clinical trials.

0

4

0

1

612

about 1 year ago

🇨🇳 #CSPC announced to enter into an exclusive #licensing agreement with #Cipla for the #commercialization of #irinotecan #liposome injection in the United States. Under the terms of the agreement, CSPC will grant Cipla exclusive rights to commercialize the product in the territory. CSPC will receive an upfront payment of $15 million, and is eligible for up to $25 million in potential initial commercial sales and regulatory milestone payments, as well as up to $1.025 billion in potential additional commercial sales milestone payments. In addition, CSPC will receive double-digit tiered royalties based on the product’s annual net sales in the territory. https://t.co/vt74w0AaBO

0

3

0

644